<DOC>
	<DOCNO>NCT00855257</DOCNO>
	<brief_summary>The investigator ' work proposes evaluate effectiveness Acid Nicotinique ( Niaspan® ) , molecule currently market , ready raise plasmatic level HDL-c . This effectiveness test among patient present recently acute coronary syndrome . The effectiveness molecule appreciate versus placebo randomization . The technique evaluation effectiveness analysis vasodilatation endothelial-dependent measure level huméral ( echography high resolution ) . The awaited result improvement 2 % value absolute vasodilatation initial test end study patient receive acid nicotinic versus receive placebo ( 3 month treatment inclusion ) . The calculation sample necessary achieve goal envisages 70 patient lead end study , divide two group treatment ( acid nicotinic Placebo ) . Such result obtain would high find study evaluate effect vasomotricity endothelial statin inhibitor enzyme conversion .</brief_summary>
	<brief_title>Assessment Endothelial Vasomotricity After Treatment Nicotinic Acid Acute Coronary Syndrome</brief_title>
	<detailed_description>The pharmacological assumption responsibility coronary disease rest partially year regulation inhibitor HMG CoA reductase ( statin ) . These drug initially address quantitative anomaly Lipoproteins low density ( LDL cholesterol ) . The objective lay national recommendation ( obtain plasmatic rate &lt; 1gr/l coronary secondary prevention among patient high vascular risk ) international , implies broad regulation wan coronary syndrome . It exist addition among many patient qualitative quantitative anomaly Lipoproteins High density ( HDL-c ) whose correlation coronary risk beforehand largely show . The anomaly HDL-c sensitive hygieno-dietetic rule . To intervene plasmatic level lipoproteins thus essential improvement forecast proven coronary patient . The investigator know since begin year 1980 ( work Furchgott Moncada ) endothelium powerful integrator vascular risk , particular aspect regulation vasomotrice . Methods investigation endothelium develop coronary floor level peripheral artery analyze vasomotricity endothelial dependent . Among method study vasomotricity level huméral validate , largely use correlate many test forecast patient present high vascular risk .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>informed consent write patient Acute coronary syndrome go back less 7 day rise high 0.10 troponin associate least one follow element : ( symptom myocardiac ischaemia , appearance pathological wave Q , disturb repolarisation connection ischaemia ( know shift segment ST ) . HDL C low 0.4 g/l FMD &lt; 7 % Antecedents myopathy induce statin severe reaction oversensitiveness inhibitor HMG CoA réductase ( statin ) . Antecedent family hypercholesterolemia homozygote type . Women pregnant , nursing , likely pregnant use chemical mechanical contraception present positive test pregnancy blood ( bHCG ) . Subjects whose substitute hormonal treatment oral contraception initiate 3 previous month Visit 0 . Active hepatic pathology hepatocellular insufficiency ( doubly gammas WP ; TGP &gt; 3 time normal ) Renal insufficiency engrave clearance creatinin &lt; 30 ml/min . LDL &lt; 0.70gr/l , triglycerides ³ 400 Mg dL ( 4.52 mmol/L ) , hbA1c &gt; 8.5 % , HDL cholesterol &gt; 0 40g/l . Evolutionary cancer Use follow concomitant treatment : insulin , nitrated derivative Antecedents alcoholism and/or catch dope last year . CPK ³ 3 time higher limit normal fraction MB CPK &lt; 2 time limit high normal visit 1 . If CKMB available , one take account value CPK &gt; 3 time limit high normal cardiac Troponin ( I T ) &lt; 0.10 g/l visit 1 . Clinical history permanent systolic hypotension ( NOT &lt; 90 mmHg ) permanent control hypertension ( NOT &gt; 200 mmHg gold PAD &gt; 110 mmHg ) . Coronary bridge 3 month inclusion ( V1 ) . Occurred fibrillation ventricular , tachycardia ventricular constant ( RIVETTED ) , complete permanent auriculoventricular Bloc , occur auricular fibrillation ventricular rate/rhythm control ( &gt; 130 bpm ) , ventricular rate/rhythm 4 week precede visit 1 . Cerebral vascular accident , severe infection , péricardite acute obviousness know systemic embolism control Hypothyroïdie define rate TSH &gt; 1,5 time higher limit normal Serious unstable condition psychological medical accord opinion investigator , would compromise safety patient participation study . Participation another clinical trial ( register raise biomedical law research ) treatment study receive treatment study 4 week precede inclusion study . Patients supervision trusteeship without Social Security cover impossibility follow specific procedure study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Acid nicotinique</keyword>
	<keyword>FLOW MEDIATED DILATATION ( FMD )</keyword>
	<keyword>HDL-C &lt; 0.4 G/L</keyword>
</DOC>